background logo image

Episode 231

New Study: Could GLP-1 Medications Be Reducing Physical Activity?

Listen, Watch & Subscribe on:

Watch

New Study: Could GLP-1 Medications Be Reducing Physical Activity?

Listen

About the host

Bret Scher, MD

Bret Scher, MD

Medical Director

Bret is the host of the Metabolic Mind YouTube channel and podcast. He is a board-certified cardiologist, lipidologist, and leading expert in therapeutic uses of metabolic therapies, including ketogenic diets. Prior to joining Baszucki Group, Bret was the medical director at DietDoctor.com, an online platform promoting improving metabolic health through low-carb nutrition, where he was a content creator and medical reviewer. Earlier in his career, he worked as a cardiologist in San Diego. Bret has spent most of his 20-year career as a preventive cardiologist, helping people improve their metabolic health and preventing heart disease using low-carb nutrition and lifestyle interventions. His deep passion for educating the public about the benefits of metabolic therapies grew from his experience with the prevailing medical teaching, which frequently misrepresents nutrition science and undervalues metabolic health. Bret received an MD from The Ohio State University College of Medicine and a BS in Biology from Stanford University. He grew up in San Diego and began competing in triathlons at an early age, which helped fuel his love of health and fitness. He continues to enjoy spending time outdoors mountain biking, swimming, hiking, and playing baseball with his two boys.
Learn more about Bret

Bret Scher, MD

Medical Director

Bret is the host of the Metabolic Mind YouTube channel and podcast. He is a board-certified cardiologist, lipidologist, and leading expert in therapeutic uses of metabolic therapies, including ketogenic diets. Prior to joining Baszucki Group, Bret was the medical director at DietDoctor.com, an online platform promoting improving metabolic health through low-carb nutrition, where he was a content creator and medical reviewer. Earlier in his career, he worked as a cardiologist in San Diego. Bret has spent most of his 20-year career as a preventive cardiologist, helping people improve their metabolic health and preventing heart disease using low-carb nutrition and lifestyle interventions. His deep passion for educating the public about the benefits of metabolic therapies grew from his experience with the prevailing medical teaching, which frequently misrepresents nutrition science and undervalues metabolic health. Bret received an MD from The Ohio State University College of Medicine and a BS in Biology from Stanford University. He grew up in San Diego and began competing in triathlons at an early age, which helped fuel his love of health and fitness. He continues to enjoy spending time outdoors mountain biking, swimming, hiking, and playing baseball with his two boys.
Learn more about Bret

Key Highlights

  • A retrospective study presented at the Endocrine Society meeting found that adults on GLP-1 medications significantly reduced physical activity after starting treatment, with average daily steps dropping from 5,047 to 4,487 and moderate to vigorous activity falling from 28 to 22 minutes per day.
  • Bret argues this isn’t isolated to GLP-1s, drawing parallels to statins, where a health halo effect can lead patients to unconsciously relax diet and exercise habits, and to antipsychotics, which can cause dramatic weight gain with little accompanying lifestyle support.
  • He explains that GLP-1 side effects like fatigue, nausea, and GI symptoms directly reduce energy and motivation to exercise, compounded by the body’s natural response to rapid caloric restriction, which down-regulates non-exercise activity thermogenesis and further decreases movement.
  • The study found the largest activity declines occurred in patients with pre-existing joint pain or physical limitations, who Bret argues need the most specific, structured exercise guidance rather than generic encouragement to move more.
  • Bret calls for exercise prescriptions to be personalized and discussed at the time of prescribing, physical activity to be assessed at every follow-up visit, and for consideration of covering activity monitors, physical therapy, or personal trainers, since a drug that reduces appetite, muscle mass, and physical activity isn’t reaching its full potential without a structured movement plan alongside it.

Transcript

Listen, Watch & Subscribe on:

You May Also Be Interested In:

Psychiatry Research Priorities: Keto, GLP-1s, Exercise & Mental Illness
Podcast

Psychiatry Research Priorities: Keto, GLP-1s, Exercise & Mental Illness

Dr. Bret Scher speaks with Dr. Toby Pillinger and Dr. Dina Farran of King's College London about their year-long priority setting partnership, a structured process bringing together patients, caregivers, and clinicians to determine the top 10 research questions on metabolic interventions for serious mental illness. The conversation covers how the project was built, what people actually want researched, and why the results reveal a striking shift in how patients themselves view the role of metabolism in psychiatric illness.

Read more

GLP-1s, Weight Loss, and the Stigma We Don’t Talk About
Podcast

GLP-1s, Weight Loss, and the Stigma We Don’t Talk About

Dr. Bret Scher reflects on a New York Post report showing people who lose weight with GLP-1 drugs face more stigma than those who don't lose weight at all, prompting him to examine his own criticism of these medications. He clarifies his concern isn't with patients choosing this tool, but with clinicians who prescribe GLP-1s without pairing them with lifestyle interventions, arguing the medical system needs to prioritize long-term metabolic health over quick fixes.

Learn more

Do GLP-1s Work for Depression—or Is It Metabolism?
Podcast

Do GLP-1s Work for Depression—or Is It Metabolism?

Dr. Bret Scher examines a new Lancet Psychiatry study on GLP-1 medications and mental health, finding that people with type 2 diabetes on GLP-1s like semaglutide had fewer severe psychiatric outcomes than those on other diabetes drugs. He explains this reflects "less worsening" rather than actual improvement in depression or anxiety, and explores how the findings fit into the broader emerging field connecting metabolic health and mental health, including ketogenic therapy.

Learn more

GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals
Podcast

GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals

Dr. Bret Scher examines a new BMJ Medicine study showing GLP-1 medications like semaglutide reduce cardiovascular risk, but only after 18 months of continuous use, and those benefits disappear within 18 months of stopping. He argues this reveals GLP-1s manage symptoms rather than fix underlying metabolic drivers, and makes the case for pairing these medications with sustainable nutrition and lifestyle changes rather than accepting lifelong dependence as the default.

Learn more

Psychiatry Research Priorities: Keto, GLP-1s, Exercise & Mental Illness
Podcast

Psychiatry Research Priorities: Keto, GLP-1s, Exercise & Mental Illness

Dr. Bret Scher speaks with Dr. Toby Pillinger and Dr. Dina Farran of King's College London about their year-long priority setting partnership, a structured process bringing together patients, caregivers, and clinicians to determine the top 10 research questions on metabolic interventions for serious mental illness. The conversation covers how the project was built, what people actually want researched, and why the results reveal a striking shift in how patients themselves view the role of metabolism in psychiatric illness.

Read more

GLP-1s, Weight Loss, and the Stigma We Don’t Talk About
Podcast

GLP-1s, Weight Loss, and the Stigma We Don’t Talk About

Dr. Bret Scher reflects on a New York Post report showing people who lose weight with GLP-1 drugs face more stigma than those who don't lose weight at all, prompting him to examine his own criticism of these medications. He clarifies his concern isn't with patients choosing this tool, but with clinicians who prescribe GLP-1s without pairing them with lifestyle interventions, arguing the medical system needs to prioritize long-term metabolic health over quick fixes.

Learn more

Do GLP-1s Work for Depression—or Is It Metabolism?
Podcast

Do GLP-1s Work for Depression—or Is It Metabolism?

Dr. Bret Scher examines a new Lancet Psychiatry study on GLP-1 medications and mental health, finding that people with type 2 diabetes on GLP-1s like semaglutide had fewer severe psychiatric outcomes than those on other diabetes drugs. He explains this reflects "less worsening" rather than actual improvement in depression or anxiety, and explores how the findings fit into the broader emerging field connecting metabolic health and mental health, including ketogenic therapy.

Learn more

GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals
Podcast

GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals

Dr. Bret Scher examines a new BMJ Medicine study showing GLP-1 medications like semaglutide reduce cardiovascular risk, but only after 18 months of continuous use, and those benefits disappear within 18 months of stopping. He argues this reveals GLP-1s manage symptoms rather than fix underlying metabolic drivers, and makes the case for pairing these medications with sustainable nutrition and lifestyle changes rather than accepting lifelong dependence as the default.

Learn more